within Pharmacolibrary.Drugs.ATC.L;

model L01EM03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.79,
    Cl             = 0.15333333333333332,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.114,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0057666666666666665,
    Tlag           = 25.2
  );

  annotation(Documentation(
    info ="<html><body><p>Alpelisib is an orally bioavailable selective inhibitor of phosphatidylinositol 3-kinase alpha (PI3Kα) isoform. It is primarily indicated and approved for the treatment of hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, used in combination with endocrine therapy. The drug is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in adult patients with advanced solid malignancies or metastatic breast cancer after administration of oral alpelisib 300 mg, the approved therapeutic dose.</p><h4>References</h4><ol><li><p>Royer, B, et al., &amp; Schmitt, A (2023). Pharmacokinetics and Pharmacodynamic of Alpelisib. <i>Clinical pharmacokinetics</i> 62(1) 45–53. DOI:<a href=&quot;https://doi.org/10.1007/s40262-022-01195-2&quot;>10.1007/s40262-022-01195-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36633813/&quot;>https://pubmed.ncbi.nlm.nih.gov/36633813</a></p></li><li><p>Marbury, T, et al., &amp; Preston, RA (2023). Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study. <i>Journal of Cancer</i> 14(9) 1571–1578. DOI:<a href=&quot;https://doi.org/10.7150/jca.82736&quot;>10.7150/jca.82736</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37325049/&quot;>https://pubmed.ncbi.nlm.nih.gov/37325049</a></p></li><li><p>Jhaveri, KL, et al., &amp; Beeram, M (2024). Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 42(35) 4173–4186. DOI:<a href=&quot;https://doi.org/10.1200/JCO.23.02733&quot;>10.1200/JCO.23.02733</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39241211/&quot;>https://pubmed.ncbi.nlm.nih.gov/39241211</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EM03;
